Partners

They support us

Partners

They support us

ALCEDIAG, partners meeting

SYNLAB

myEDIT-B test is at the heart of an exclusive European partnership with the Synlab group of medical laboratories, the market leader in Europe, which has become myEDIT-B test’s distributor.

BPI, France Relance et France 2030

The SEM EDIT-B project aims to validate the clinical utility of the EDIT-B test for unipolar and bipolar depressed patients and perform a health economics study for EDIT-B. This project was financed by the French Government as part of France 2030 and by the European Union – Next Generation EU as part of the France Relance plan.

EIT Health

The EDIT-B Consortium and project aim to solve the bipolar disorder diagnostic challenge by using specific RNA editing based biomarkers and artificial intelligence to validate and commercialize a high performance and quick blood test to diagnose bipolar disorder.

Neuroderisk

NeuroDeRisk is an “Innovative Medicines Initiative” (IMI2) project aiming to provide novel validated integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system and thus help to de-risk drug candidates earlier in the Research and Development phases.

Occitanie

La région Occitanie supported the clinical development and validation of EDIT-B

Academic partners

CNRS

GHU

Hospital Clinic Barcelona

ALCEDIAG has a recurring partnership with Sys2Diag, a laboratory from the CNRS (French National Center for Scientific Research). Sys2Diag runs cutting edge research for innovation in medical diagnosis and next generation medical interactives devices engineering.

ALCEDIAG is engaged into a recurring partnership with GHU Paris Psychiatrie & Neurosciences, the leading hospital player in mental illnesses and the nervous system in France.

ALCEDIAG is engaged into a recurring partnership with Hospital Clinic Barcelona, a leading healthcare, research and teaching center in Barcelona.

Others Partners

Impulsion - Villa M

Groupe Pasteur Mutualité and « iMpulsion-Villa M » acceleration programme

Villa M-Paris has created its ‘iMpulsion-Villa M’ acceleration programme in association with Groupe Pasteur Mutualité. This program of 8-months brings together around ten innovative start-ups in the health and e-health sector. The aim of the programme is to support them in the deployment of their innovative healthcare products, in order to improve the lives of millions of people. Groupe Pasteur Mutualité is a mutual insurance and services group for healthcare professionals.

ALCEDIAG – iMpulsion Villa M (villa-m.fr)

Impulsion - Villa M

HopeStage

ALCEDIAG is collaborating with HopeStage, a combined company and association dedicated to supporting people concerned by bipolar disorder. Clément Baissat, the founder of HopeStage, has devised a 4-step support approach: “AWARE” – “ACCEPT” – “GUIDE” – “SUPPORT”. Its mission is to reduce the stigma attached to bipolar disorder and to help patients deal with the condition from the very first symptoms. Together, we want to help people with bipolar disorder to live a better and balanced life.

HopeStage Website

Bipolarite France

ALCEDIAG worked with Bipolarite France, a patient association focusing on bipolar disorder with patients at the center of their action on the impact of delayed diagnosis on patients.

France Biotech

ALCEDIAG is a member of France Biotech, the French trade association of biotechnology companies.

Medicen

ALCEDIAG is a member of Medicen the Île-de-France / Paris competitiveness cluster focusing on health, gathering more than 510 innovators in health. 

Eurobiomed

ALCEDIAG is a member of Eurobiomed, the South of France competitiveness cluster, dedicated to Healthtech, bringing together more than 400 industrial players, research laboratories, universities, etc.